HRP20211031T1 - Postupak za proizvodnju novog spoja koji sadrži dušik ili njegove soli i proizvodnja njihovog međuprodukta - Google Patents
Postupak za proizvodnju novog spoja koji sadrži dušik ili njegove soli i proizvodnja njihovog međuprodukta Download PDFInfo
- Publication number
- HRP20211031T1 HRP20211031T1 HRP20211031TT HRP20211031T HRP20211031T1 HR P20211031 T1 HRP20211031 T1 HR P20211031T1 HR P20211031T T HRP20211031T T HR P20211031TT HR P20211031 T HRP20211031 T HR P20211031T HR P20211031 T1 HRP20211031 T1 HR P20211031T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- formula
- integer
- image
- salt
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims 18
- 238000004519 manufacturing process Methods 0.000 title claims 13
- -1 nitrogen-containing compound Chemical class 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 20
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 5
- 125000006239 protecting group Chemical group 0.000 claims 5
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 3
- 238000010511 deprotection reaction Methods 0.000 claims 3
- 229910021645 metal ion Inorganic materials 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 3
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 238000006243 chemical reaction Methods 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 1
- 150000004696 coordination complex Chemical class 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D255/00—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00
- C07D255/02—Heterocyclic compounds containing rings having three nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D249/00 - C07D253/00 not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
- C07F1/08—Copper compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/003—Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015062306 | 2015-03-25 | ||
| EP16768957.9A EP3275883B1 (en) | 2015-03-25 | 2016-03-25 | Method for producing novel nitrogen-containing compound or salt thereof, and production intermediate of same |
| PCT/JP2016/059729 WO2016153054A1 (ja) | 2015-03-25 | 2016-03-25 | 新規な含窒素化合物またはその塩の製造方法およびそれらの製造中間体 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211031T1 true HRP20211031T1 (hr) | 2021-10-01 |
Family
ID=56977546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211031TT HRP20211031T1 (hr) | 2015-03-25 | 2021-06-29 | Postupak za proizvodnju novog spoja koji sadrži dušik ili njegove soli i proizvodnja njihovog međuprodukta |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20180008583A1 (ko) |
| EP (3) | EP3275883B1 (ko) |
| JP (1) | JP6411634B2 (ko) |
| KR (1) | KR102029746B1 (ko) |
| CN (2) | CN107428755B (ko) |
| AU (4) | AU2016237099C1 (ko) |
| BR (1) | BR112017020484B1 (ko) |
| CA (1) | CA2980268C (ko) |
| CO (1) | CO2017010806A2 (ko) |
| CY (1) | CY1124387T1 (ko) |
| DK (1) | DK3275883T3 (ko) |
| ES (1) | ES2877707T3 (ko) |
| HR (1) | HRP20211031T1 (ko) |
| HU (1) | HUE059670T2 (ko) |
| IL (4) | IL254532B (ko) |
| LT (1) | LT3275883T (ko) |
| MX (3) | MX2017012184A (ko) |
| PL (1) | PL3275883T3 (ko) |
| PT (1) | PT3275883T (ko) |
| RS (1) | RS62165B1 (ko) |
| RU (2) | RU2720989C2 (ko) |
| SG (2) | SG11201707899SA (ko) |
| SI (1) | SI3275883T1 (ko) |
| WO (1) | WO2016153054A1 (ko) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4249471A3 (en) | 2013-09-24 | 2023-10-18 | FUJIFILM Corporation | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof |
| RU2769702C2 (ru) | 2017-02-28 | 2022-04-05 | Морфик Терапьютик, Инк. | Ингибиторы интегрина avb6 |
| MA47692A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
| MX2021002181A (es) | 2018-08-29 | 2021-07-15 | Morphic Therapeutic Inc | Inhibicion de la integrina alfa v beta 6. |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| CN113853220A (zh) * | 2019-03-11 | 2021-12-28 | 生物相容英国有限公司 | 用于中枢神经系统肿瘤治疗的放射性微球 |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| CN116782956A (zh) | 2020-12-21 | 2023-09-19 | 先进加速剂应用国际股份公司 | 用作诊疗剂的放射性标记的α-Vβ-3和/或α-Vβ-5整合素拮抗剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5941386B2 (ja) | 1977-01-14 | 1984-10-06 | 株式会社紀文 | 高蛋白水産練製品様食品の製法 |
| DE19534177A1 (de) | 1995-09-15 | 1997-03-20 | Merck Patent Gmbh | Cyclische Adhäsionsinhibitoren |
| US6130231A (en) | 1996-11-27 | 2000-10-10 | Dupont Pharmaceuticals | Integrin receptor antagonists |
| HUP0100397A3 (en) * | 1997-12-17 | 2002-10-28 | Merck & Co Inc | Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation |
| US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
| IL142958A0 (en) * | 1998-12-18 | 2002-04-21 | Du Pont Pharm Co | Vitronectin receptor antagonist pharmaceuticals |
| TR200101775T2 (tr) * | 1998-12-18 | 2002-07-22 | Dupont Pharmaceuticals Company | Vitronektin alıcı antagonist farmasötikler |
| CA2397665A1 (en) | 2000-01-24 | 2001-07-26 | Merck & Co., Inc. | Alpha v integrin receptor antagonists |
| CA2413957A1 (en) * | 2000-06-21 | 2001-12-27 | Bristol-Myers Squibb Pharma Company | Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| CA2436130A1 (en) * | 2001-01-29 | 2002-08-08 | 3-Dimensional Pharmaceuticals, Inc. | Substituted indoles and their use as integrin antagonists |
| KR101383655B1 (ko) | 2010-05-24 | 2014-04-10 | 주식회사 바이오이미징코리아 | 트리카르보닐 테크네슘-99ｍ 또는 레늄-188 표지 고리 알지디 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 질환의 진단 또는 치료용 약학적 조성물 |
| FR2968999B1 (fr) * | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
| FR2980364B1 (fr) * | 2011-09-26 | 2018-08-31 | Guerbet | Nanoemulsions et leur utilisation comme agents de contraste |
| WO2013048996A1 (en) | 2011-09-30 | 2013-04-04 | Ge Healthcare Limited | Method for the purification of a peptide-based imaging agent precursor |
| EP2840080B1 (en) * | 2012-04-17 | 2017-12-06 | FUJIFILM Corporation | Nitrogen-containing heterocyclic compound or salt thereof |
| FR3001154B1 (fr) * | 2013-01-23 | 2015-06-26 | Guerbet Sa | Magneto-emulsion vectorisee |
| EP4249471A3 (en) * | 2013-09-24 | 2023-10-18 | FUJIFILM Corporation | Pharmaceutical composition of a nitrogen-containing compound or salt thereof, or metal complex thereof |
-
2016
- 2016-03-25 EP EP16768957.9A patent/EP3275883B1/en active Active
- 2016-03-25 RU RU2017133107A patent/RU2720989C2/ru active
- 2016-03-25 ES ES16768957T patent/ES2877707T3/es active Active
- 2016-03-25 EP EP22170836.5A patent/EP4059936A1/en active Pending
- 2016-03-25 PL PL16768957T patent/PL3275883T3/pl unknown
- 2016-03-25 EP EP21168086.3A patent/EP3872079A1/en not_active Withdrawn
- 2016-03-25 DK DK16768957.9T patent/DK3275883T3/da active
- 2016-03-25 KR KR1020177026236A patent/KR102029746B1/ko active IP Right Grant
- 2016-03-25 PT PT167689579T patent/PT3275883T/pt unknown
- 2016-03-25 RU RU2020115068A patent/RU2767398C2/ru active
- 2016-03-25 AU AU2016237099A patent/AU2016237099C1/en active Active
- 2016-03-25 BR BR112017020484-3A patent/BR112017020484B1/pt active IP Right Grant
- 2016-03-25 SG SG11201707899SA patent/SG11201707899SA/en unknown
- 2016-03-25 LT LTEPPCT/JP2016/059729T patent/LT3275883T/lt unknown
- 2016-03-25 RS RS20210779A patent/RS62165B1/sr unknown
- 2016-03-25 CN CN201680018240.1A patent/CN107428755B/zh active Active
- 2016-03-25 HU HUE16768957A patent/HUE059670T2/hu unknown
- 2016-03-25 SG SG10201902609TA patent/SG10201902609TA/en unknown
- 2016-03-25 JP JP2017508476A patent/JP6411634B2/ja active Active
- 2016-03-25 CA CA2980268A patent/CA2980268C/en active Active
- 2016-03-25 WO PCT/JP2016/059729 patent/WO2016153054A1/ja active Application Filing
- 2016-03-25 CN CN202010084360.XA patent/CN111171026B/zh active Active
- 2016-03-25 SI SI201631232T patent/SI3275883T1/sl unknown
- 2016-03-25 MX MX2017012184A patent/MX2017012184A/es unknown
-
2017
- 2017-09-17 IL IL254532A patent/IL254532B/en unknown
- 2017-09-22 US US15/712,815 patent/US20180008583A1/en not_active Abandoned
- 2017-09-25 MX MX2023005704A patent/MX2023005704A/es unknown
- 2017-09-25 MX MX2023005703A patent/MX2023005703A/es unknown
- 2017-10-24 CO CONC2017/0010806A patent/CO2017010806A2/es unknown
-
2019
- 2019-10-10 AU AU2019246859A patent/AU2019246859B2/en active Active
-
2020
- 2020-09-29 US US17/037,103 patent/US20210015802A1/en not_active Abandoned
- 2020-10-02 AU AU2020244578A patent/AU2020244578B2/en active Active
- 2020-10-02 AU AU2020244580A patent/AU2020244580B2/en active Active
-
2021
- 2021-05-18 IL IL283224A patent/IL283224B/en unknown
- 2021-05-19 IL IL283289A patent/IL283289B/en unknown
- 2021-05-19 IL IL283288A patent/IL283288B/en unknown
- 2021-06-29 HR HRP20211031TT patent/HRP20211031T1/hr unknown
- 2021-07-02 CY CY20211100591T patent/CY1124387T1/el unknown
-
2023
- 2023-02-21 US US18/112,423 patent/US20240108607A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211031T1 (hr) | Postupak za proizvodnju novog spoja koji sadrži dušik ili njegove soli i proizvodnja njihovog međuprodukta | |
| AR076435A1 (es) | Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos | |
| AR087919A1 (es) | Heterociclos biciclicos como inhibidores de irak4 | |
| MX349969B (es) | Metodos de preparación de ribósido de nicotinamida y sus derivados. | |
| NO331165B1 (no) | Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter | |
| AR061667A1 (es) | Arilamidas sustituidas con tetrazol | |
| AR055057A1 (es) | Inhibidores heterociclicos de mek, formas cristalinas de los mismos, procesos para su preparacion y metodos de uso de los mismos en composiciones farmaceuticas y medicamentos para el tratamiento de un trastorno hiperproliferativo o de una condicion inflamatoria. | |
| CO6801736A2 (es) | Derivados heterocíclicos de amina | |
| WO2005012304A3 (en) | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | |
| CO6321170A2 (es) | Heterociclos fusionados de ciclobutoxi amino y usos terapeuticos de los mismos | |
| AR107633A1 (es) | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico | |
| ES2653265T3 (es) | Morfinanos sustituidos y el uso de éstos | |
| AR062677A1 (es) | Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden | |
| JP2016506958A5 (ko) | ||
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| CY1114927T1 (el) | Νεα 2-υποκατεστημενα παραγωγα μεθυλο πεναμης | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| ES2526902T3 (es) | Procesos de producción de inhibidores de la girasa y topoisomerasa IV | |
| MX2016006685A (es) | Compuestos heterociclicos de n-acilimino. | |
| AR050005A1 (es) | Procedimiento para preparar 3-fenil(tio)uracilos y -ditiouracilos y carbamatos utiles como intermediarios para dicho proceso. | |
| AR088625A1 (es) | Derivados de aril-quinolina | |
| WO2009010789A3 (en) | Pyrimidine derivatives 934 | |
| AR098871A1 (es) | Métodos de proceso para inhibidores de fosfatidilinositol 3-quinasa | |
| AR068376A1 (es) | Amidas heterociclicas utiles para inhibir la via hedgehog. | |
| BR112013001721A2 (pt) | processo de síntese de compostos de ureia substituída |